HELIX, INC. for HELIX, INC.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 8, 2022 | $36,520 | Replaced |
| 2nd Quarter - Amendment (this page) | Aug 3, 2023 | $110,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Genomic research and testing, pandemic preparedness, viral surveillance, regulation of Lab Developed Tests in VALID ACT USH 4128 and PREVENT Act. Also US H 791 COVID-19 Variant Data Tracking, USH 6589 Clinical Trial Diversity. USH 7667 Rx Drug and Device User Fees, US S 236 COVID-19 Variants Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELLI ARTHUR HYKES | — |
Medical/Disease Research/Clinical Labs MED
genomic research and testing, COVID-19 testing,research, and respiratory pathogen sequencing and surveillance, Lab Developed Tests USH 4128
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELLI ARTHUR HYKES New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.